In 2021, we will launch our first recombinant GMP grade enzyme aimed at the biopharmaceutical and regenerative medicine market. In order to support the launch and subsequent product launches, we are establishing a sales office in the US. When implemented mid-2021, Novo Nordisk Pharmatech will have a presence in Singapore, Copenhagen and Boston and will be optimally geographically positioned to support our customers globally.
We will continue our efforts and complete our investments in a new multipurpose facility to handle a more diverse enzymatic product portfolio. This will enable us to serve the Novo Nordisk demand of materials to produce newly launched products within diabetes care. This facility is also expected to fuel the longer-term growth of Novo Nordisk Pharmatech. In 2021, we expect an increased demand for purification resins for Novo Nordisk and will also invest in a new facility for a novel optimised purification resin.
At Novo Nordisk Pharmatech A/S we are committed to bringing forward pharmaceutical materials that enable better medicines for our customers in a sustainable way. If you want to be a part of our journey you can always see any vacant positions here.